A randomized, multicentral, phase III study of parallel groups to compare the efficiency and tolerance of fulvestrant administered for three years in combination with anastrozol for 5 years versus anastrozol for 5 years as adjuvant hormonotherapy in postmenopausal women with early breast cancer and + HRs [hormonal receptors positive].

Trial Profile

A randomized, multicentral, phase III study of parallel groups to compare the efficiency and tolerance of fulvestrant administered for three years in combination with anastrozol for 5 years versus anastrozol for 5 years as adjuvant hormonotherapy in postmenopausal women with early breast cancer and + HRs [hormonal receptors positive].

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Fulvestrant (Primary) ; Anastrozole
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Oct 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 09 Aug 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 05 Nov 2008 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top